​

Immunovant (IMVT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

IMVT Stock Forecast

Immunovant (IMVT) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $45.50, with a high of $50.00 and a low of $41.00. This represents a 57.38% increase from the last price of $28.91.

$20 $26 $32 $38 $44 $50 High: $50 Avg: $45.5 Low: $41 Last Closed Price: $28.91

IMVT Stock Rating

Immunovant stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (78.26%), 4 Hold (17.39%), 1 Sell (4.35%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 1 4 18 Strong Sell Sell Hold Buy Strong Buy

IMVT Price Target Upside V Benchmarks

TypeNameUpside
StockImmunovant57.38%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$35.67
Last Closing Price$28.91$28.91$28.91
Upside/Downside--23.38%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 262115--18
Mar, 262114--17
Feb, 262114--17
Jan, 262105--17
Dec, 252105--17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 06, 2026Wolfe Research$50.00$24.97100.24%72.95%
Dec 18, 2025Yatin SunejaGuggenheim$41.00$26.2756.07%41.82%
Oct 14, 2025Truist Financial$16.00$17.35-7.78%-44.66%
Sep 10, 2024Douglas TsaoH.C. Wainwright$51.00$30.2068.87%76.41%
Jun 03, 2024Leland GershellOppenheimer$46.00$25.3981.17%59.11%
May 30, 2024Yatin SunejaGuggenheim$48.00$26.4181.75%66.03%
May 30, 2024Yasmeen RahimiPiper Sandler$57.00$27.83104.81%97.16%
Mar 13, 2024Corinne JohnsonGoldman Sachs$50.00$31.8257.13%72.95%
Sep 26, 2022Colin BristowUBS$5.00$4.882.46%-82.70%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 15, 2026Goldman SachsNeutralNeutralhold
Feb 09, 2026GuggenheimBuyBuyhold
Jan 06, 2026Wolfe ResearchPeer PerformOutperformupgrade
Dec 18, 2025GuggenheimBuyBuyhold
Aug 11, 2025CitigroupBuyBuyhold
Mar 02, 2025JefferiesMixedMixedhold
Jan 03, 2025Wolfe ResearchPeer PerformPeer Performdowngrade
Dec 19, 2024Wells FargoOverweightOverweighthold
Oct 09, 2024OppenheimerOutperformOutperformhold
Sep 25, 2024Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.88$-2.73----
Avg Forecast$-1.79$-2.88$-3.17$-3.47$-2.79$-0.69
High Forecast$-1.71$-1.97$-2.80$-1.82$-0.70$-0.17
Low Forecast$-1.86$-3.11$-3.50$-4.59$-6.62$-1.63
Surprise %5.03%-5.21%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported------
Avg Forecast-$30.10M$32.43M$31.66M$204.88M$697.32M
High Forecast-$61.86M$76.56M$65.07M$421.08M$1.43B
Low Forecast-$12.78M$8.36M$13.44M$86.99M$296.06M
Surprise %------

Net Income Forecast

$-950M $-760M $-570M $-380M $-190M $0 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-259.34M$-413.84M----
Avg Forecast$-243.45M$-350.40M$-434.68M$-592.31M$-385.69M$-95.09M
High Forecast$-235.98M$-271.65M$-386.38M$-250.86M$-97.17M$-23.96M
Low Forecast$-256.80M$-429.15M$-482.98M$-633.40M$-914.78M$-225.54M
Surprise %6.53%18.11%----

IMVT Forecast FAQ

Is Immunovant stock a buy?

Immunovant stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Immunovant is a favorable investment for most analysts.

What is Immunovant's price target?

Immunovant's price target, set by 23 Wall Street analysts, averages $45.5 over the next 12 months. The price target range spans from $41 at the low end to $50 at the high end, suggesting a potential 57.38% change from the previous closing price of $28.91.

How does Immunovant stock forecast compare to its benchmarks?

Immunovant's stock forecast shows a 57.38% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Immunovant over the past three months?

  • April 2026: 11.11% Strong Buy, 61.11% Buy, 27.78% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 11.76% Strong Buy, 64.71% Buy, 23.53% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 11.76% Strong Buy, 64.71% Buy, 23.53% Hold, 0% Sell, 0% Strong Sell.

What is Immunovant’s EPS forecast?

Immunovant's average annual EPS forecast for its fiscal year ending in March 2026 is $-3.17, marking a 16.12% increase from the reported $-2.73 in 2025. Estimates for the following years are $-3.47 in 2027, $-2.79 in 2028, and $-0.69 in 2029.

What is Immunovant’s revenue forecast?

Immunovant's average annual revenue forecast for its fiscal year ending in March 2026 is $32.43M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $31.66M, followed by $204.88M for 2028, and $697.32M for 2029.

What is Immunovant’s net income forecast?

Immunovant's net income forecast for the fiscal year ending in March 2026 stands at $-435M, representing an 5.04% increase from the reported $-414M in 2025. Projections indicate $-592M in 2027, $-386M in 2028, and $-95.092M in 2029.